Hospital Ruber Internacional

Hospital Ruber Internacional’s neurology team is advancing the treatment of epilepsy and related encephalopathies through studies that assess safety and seizure‑reduction potential of emerging medicines.

• Adult focal (partial onset) epilepsy
• Refractory focal onset epilepsy
• Dravet syndrome and Lennox‑Gastaut syndrome
• Developmental and epileptic encephalopathies (DEE)
• Epilepsy associated with tuberous sclerosis complex
• KCNT1‑related developmental encephalopathy

The goal is to improve seizure control and quality of life for patients with rare and treatment‑resistant seizure disorders.

In the oncology unit, investigators are evaluating a biosimilar to Opdivo for patients with advanced melanoma, focusing on comparable efficacy and safety.

• Previously untreated unresectable melanoma
• Metastatic stage III/IV melanoma
• First‑line immunotherapy with nivolumab biosimilar

These trials aim to broaden access to effective immunotherapy options while maintaining clinical outcomes.

The department conducts research on prostate cancer to determine the optimal duration of androgen deprivation therapy combined with salvage radiotherapy after surgical recurrence.

• Recurrent prostate cancer post‑prostatectomy
• Short‑term versus long‑term ADT
• Salvage radiotherapy integration

Findings are expected to refine treatment protocols and improve long‑term disease‑free survival.

Studies at the site explore disease‑modifying strategies for Early Parkinson’s Disease, measuring impact on functional scores such as the MDS‑UPDRS.

• Early-stage Parkinson’s patients
• Movement Disorder Society Unified Parkinson’s Disease Rating Scale outcomes
• Time to first worsening event

The research seeks to delay progression and maintain daily living abilities for individuals newly diagnosed with Parkinson’s.

A dedicated program investigates therapies for congenital, hereditary and neonatal neurological conditions, targeting specific genetic mutations that drive severe seizure phenotypes.

• KCNT1‑related developmental and epileptic encephalopathy
• Other rare developmental encephalopathies
• Genetically driven seizure disorders

By focusing on precision medicine, the trials aim to deliver targeted treatments that address the underlying genetic causes.